Company intelligence / Profile preview
Thioredoxin Systems AB
Swedentxnsystems.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Thioredoxin Systems AB is developing EbsArgent™, an innovative antibacterial treatment targeting the bacterial antioxidant redox system. The regimen combines ebselen, which disables the essential thioredoxin enzyme system in bacteria, with silver ions to enhance uptake. This approach has demonstrated high bactericidal activity against multidrug-resistant bacteria, including those classified as critical or urgent threats by WHO and CDC. The technology shows promise for efficacy and safety with low mammalian toxicity[1][2].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules (ebselen)Metal ions (silver ions)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Thioredoxin Systems AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thioredoxin Systems AB.